EP4566611A2 — [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
Assigned to Boehringer Ingelheim International GmbH · Expires 2025-06-11 · 1y expired
What this patent protects
The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I)wherein the groups R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> have the meanings given in the claims and specificati…
USPTO Abstract
The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I)wherein the groups R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
Drugs covered by this patent
- Hernexeos (ZONGERTINIB) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.